Objective. (i) To examine the sustainability of an in-hospital quality improvement (QI) intervention, the American College of Cardiology's Guideline Applied to Practice (GAP) in acute myocardial infarction (AMI). (ii) To determine the predictors of physician adherence to AMI guidelines-recommended medication prescribing.
Introduction
Coronary heart disease remains the leading cause of death in the USA [1] . Early administration of key drugs, including aspirin/Plavix, betablockers (BBs), lipid-lowering therapy (LLT) and angiotensin-converting enzyme inhibitors (ACEIs), substantially reduces mortality and other adverse events [2] [3] [4] [5] . However, disappointing in-hospital prescription rates [6] [7] [8] appear to contribute to adverse outcomes [9] , including higher risk for recurrent acute myocardial infarction (AMI) and death. Although hospitals employ a variety of quality improvement (QI) approaches to address this problem [10] , the sustainability of improvements past the initial intervention period has rarely been studied.
We revisited five hospitals, which had recently participated in the guideline applied in practice (GAP) QI intervention to determine the 1-year sustainability of improvements and predictors of AMI guideline-recommended medication prescribing. We hypothesized that (i) QI efforts would be sustained at 1 year and (ii) patients who had percutaneous coronary intervention (PCI) would be more likely to be prescribed evidencebased medications compared with patients who had coronary artery bypass graft (CABG).
The GAP in-hospital QI intervention has been described previously [7, 11, 12] . The GAP implementation tool kit consisted of seven clinical components: (i) AMI standing orders, (ii) clinical pathways, (iii) a pocket guide/pocket card, (iv) a patient information form, (v) a patient discharge form, (vi) chart stickers and (vii) hospital performance charts [5, 7, 11] . At discharge, GAP patients also received a written contract listing all appropriate discharge medications, as well as recommendations for rehabilitation and health behavior change (smoking cessation, diet and exercise). Both the discharge planner and the patient signed the contract and the patient received a copy [5, 7, 11] .
Methods Design
This investigation was conducted as part of an Agency for Healthcare Research and Quality-funded trial assessing the effectiveness of a post-hospital health behavior change program: the Heart After-Hospital Recovery Planner (HARP) for patients diagnosed with AMI [13] . The HARP study tested the contribution of a post-discharge telephone counseling (goal setting and reinforcement) intervention to GAP discharge planning following hospitalization for AMI. Details of the HARP study are published elsewhere [13] . The in-hospital cohort analyzed in this study consisted of 516 AMI patients consecutively admitted to 5 mid-Michigan community hospitals 1 year after the implementation and conclusion of the GAP QI intervention. Thus, the current analyses compared the data from a prospective observational study to a historical cohort of patients in the same community hospitals.
Patient population
A total of 719 subjects consented to enroll in the HARP study between January 2002 and April 2003. For those enrolled, 710 complete medical record audits were obtained with largely complete information on procedures, medication use and demographics. To avoid overlap with the follow-up in the earlier GAP studies, the current analysis is confined to the 516 patients who enrolled after 1 April 2002 through the end of the HARP enrollment period at 30 April 2003. Inclusion criteria were as follows: a working diagnosis of AMI in the medical record, a documented serum troponin I level greater than the upper limits of normal and the age of 21 years or older. Patients were excluded if they were unable to speak English, complete study interviews or discharged to a non-home setting. Trained nurse recruiters approached patients during their hospitalization providing information on study participation and the opportunity to enroll in the study. Before any data collection occurred, the study was approved by the Michigan State University institutional review board (IRB) and IRBs of each of the five participating study hospitals.
Data collection
Trained chart abstractors reviewed the charts of all enrolled patients. The data collected included date of the AMI admission, demographic characteristics, symptoms, results of diagnostic electrocardiograms, relevant laboratory values, diagnostic tests, treatments and date of discharge or death. Each patient's medical record, including discharge summary and instructions, was also abstracted for pre-hospital, in-hospital and discharge medications. Each chart abstractor was supervised by the Community Project Manager and used a standard data collection sheet and referred to a chart abstraction manual concerning specific data fields and parameters. Team meetings were conducted quarterly to review and refine chart audit processes and maintain reliability of data entry.
Main measures and statistical analysis
The main outcome was adherence to GAP guideline medications. For the comparison of the current HARP study cohort with the earlier GAP cohort [11] , we constructed tables containing the same descriptive information about the medication prescriptions and procedures, presenting proportions, percentages or means and using the standard errors to estimate the significance of the differences found between the study cohorts. To establish predictors of specific discharge medication prescriptions, we employed multivariate logistic regression models [14] to obtain adjusted odds ratios (ORs) relating medication use to patients' demographic and clinical characteristics and AMI-related procedures performed during the index hospitalization.
Results

Hospital and patient characteristics
Five mid-Michigan hospitals from two urban communities participating in the GAP intervention and the HARP study ranged in bed sizes from 268 to 495. Additional hospital characteristics are shown in Table 1 . Each hospital was staffed by cardiologists, primary care physicians and resident physicians in training. Table 2 displays the demographic and clinical characteristics of enrolled patients. Overall, there were relatively fewer women among the HARP cohort (36.6 versus 42.7% in the GAP cohort). The proportion of HARP patients with prior risk factors for heart disease appeared somewhat lower, except that there were more smokers (36.8%) than in the GAP cohort (10.3%).
Comparison of rates of medication use
To compare the use of medications during hospitalization in the GAP and the HARP cohorts, the analysis of prescription rates for aspirin, BB, ACEI/angiotensin receptor blocker (ARB) and LLT included only patients ideally suited for such medications. For each medication, eligible patients were categorized as 'ideal' candidates, if they had no documented contraindications. The criteria for ideal status followed those in previous studies [7, 8, 15, 16] . Given the contraindications, the numbers of ideal candidates for use of aspirin, BBs, ACEIs, ARBs and LLT varied substantially.
As Table 3 shows, adherence to most key quality indicators remained high in the five hospitals for up to 2 years after participation in the GAP intervention; 84.5% of ideal candidates had aspirin prescribed in the first 24 h in the hospital, which is at a slightly lower rate but was not a significant decline from the 89% levels in the GAP studies (P > 0.135). In addition, 31 of the 65 ideal patients who did not have aspirin prescribed received Plavix (clopidogrel) (not shown in Table 3 , because of lack of comparison with earlier cohorts). Therefore, 91.9% of patients had aspirin or Plavix early on admission for ACS. Early use of BBs (87.9%) shows a substantial and significant (P < 0.001) increase over the earlier GAP study samples both at baseline (pre-GAP intervention) (73.6%) and at remeasurement (post-GAP intervention) (72.1%) whereas cholesterol assessment within 24 h appeared not to have changed (P > 0.225) a year after the GAP QI efforts (Table 3) . Discharge aspirin and BB followed a different pattern. Their use was higher immediately post-GAP, but fell back to baseline levels 1 year after the QI (Table 3 ). While not statistically significant, a similar pattern can be observed for the rate of prescription of discharge ACEI and treatment of patients with low-density lipoprotein (LDL) of ≥100. Furthermore, 64.8% of eligible HARP patients were prescribed aspirin/Plavix at discharge. Table 4 presents data from the HARP study cohort, relating the medication use/quality care indicators to the diagnostic and therapeutic procedures performed in the hospital. As noted, 248 (48.1%) of the 516 patients had PCI and 122 (23.6%) had CABG performed during their hospitalization whereas 111 (21.5%) patients were only catheterized and the remaining 35 (6.8%) patients had no procedures performed. 
Procedures and medication use for ACS patients
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While the total numbers of patients vary within each procedure column in Table 4 , reflecting the variation in the numbers of patients with contraindications for different medications, the overall pattern was highly consistent. Rates of all discharge medication prescriptions for PCI patients were significantly higher than for patients undergoing other procedures. In particular, these rates were significantly lower for CABG patients, except in the case of discharge aspirin. There was no significant difference between PCI and CABG patients in discharge aspirin use. Patients who underwent catheterization only also showed a trend for higher rates of discharge medications compared with patients who did not undergo any procedures, even though these comparisons did not reach statistical significance (Table 4) . As expected, patients who had PCI were more likely to use both aspirin and Plavix compared with all other AMI patients ( Table 4) .
Predictors of discharge medication prescription rates
To explore which patient characteristics or hospital procedures predicted discharge medication rates, five multivariate logistic regression models were fitted to the data, each predicting a quality indicator, i.e. the use of a specific medication among patients without contraindications (Table 5 ). Our analysis revealed that patients older than 74 years were significantly less likely to be prescribed aspirin or Plavix (OR 0.44, P < 0.05) at discharge than patients under 65 years of age. Furthermore, with the exception of BBs, there appeared to be a nonsignificant trend toward lower use of all medications for patients over the age of 64. We also observed significant gender differences in discharge prescriptions. Men were more likely to be prescribed aspirin (OR 1.96, P < 0.05) and BB (OR 2.59, P < 0.05) than women. Compared with minorities, white patients appeared less likely to be prescribed ACEI (OR 0.44 P < 0.05) and aspirin/Plavix at discharge (OR 0.47, P < 0.05). Patients with more comorbidities (Charlson Index Score > 4) were less likely to be prescribed ACEI (OR 0.23 P < 0.05) at discharge; similarly, patients with low ejection fractions (EF < 35) at hospitalization appeared less likely to be prescribed discharge medications, especially aspirin and Plavix.
In general, the multivariate analyses confirmed that in-hospital procedures were strong predictors of discharge 
Table 3 Comparison of HARP and GAP on selected quality indicators
Quality indicator
Pre-GAP cohort (n = 523) [11] GAP cohort (n = 499) [11] HARP cohort (n = 516) n/N refers to number of patients receiving medication/number of ideal candidates (without contraindications).
medication prescription. In particular, patients who underwent PCI consistently had the highest prescription rates for discharge medications, with adjusted ORs ranging from 2.6 to 6.3. Prescription of aspirin (OR 3.11, P < 0.05), LLT (OR 6.27, P < 0.001) and aspirin/Plavix (OR 3.94, P < 0.01) was all statistically significant (Table 5) . In contrast, patients who underwent bypass surgery displayed a trend toward lower use of BB, ACEIs and aspirin/Plavix (P > 0.55). Finally, prescription rates for discharge medicines did differ significantly depending on which hospital an AMI patient was admitted to. In particular, discharge prescription rates for BBs exhibited the largest differences among the hospitals, with a 7-fold difference (3.37/0.47 = 7.02) in the odds of receiving a BB prescription between hospitals C and D. However, none of the hospitals consistently displayed the highest or lowest discharge prescription rates for all the medications examined.
Discussion
This study provides an innovative first assessment of the longterm sustainability of the GAP intervention, a QI intervention with a multifaceted approach focused on providers and patients [7, 11, 17, 18] . The GAP intervention had been shown to improve adherence to key quality indicators in initial follow-up evaluations [7, 11] .
Our results show that adherence to in-hospital medications remained uniformly high in the five GAP hospitals. In the case of early administration of BB, further improvement was observed 1 year after the GAP intervention. However, prescriptions for discharge medications appeared to generally return to pre-GAP levels. This finding is consistent with results of the CRUSADE study, which found that, by the end of the study, two-thirds of patients failed to receive one or more indicated therapies [19] . Although this study did not monitor the consistent use of GAP tools, our previous GAP studies have shown that lower discharge medication rates may be due to the fact that some of the GAP tools, particularly the discharge documents, were not used for all patients despite the efforts of the GAP implementers [11, 20] . This also suggests that discharge protocols and a discharge form that emphasizes guideline-based medications, lifestyle modification and follow-up planning may not have been as robust as procedure protocols (American heart association (AHA) guidelines-based protocol for cardiac catheterization and PCI) [7] . This is an extremely important observation since the long-term positive effects of cardiac medications will be achieved in the post-discharge settings.
While some QI efforts do not always improve the process of care or outcomes [21] , the GAP intervention improved n/N refers to number of patients receiving medication/number of ideal candidates (without contraindications).
both physician performance and patient outcomes during the intervention period. Similarly, participation in the CRUSADE initiative led to significant increases in the use of each class-1 guideline recommendation, as well as greater overall guideline adherence during the study [19] . Our findings suggest that where QI was successful, the results may not be easily sustainable over the next year in typical settings. Some hospitals may not continue to use the GAP tools as recommended after the QI intervention formally ends. However, Birtcher et al. [25] found that the performance award program for 'Get With The Guidelines-Coronary Artery Disease' (GWTG-CAD) was associated with global and sustained adherence to evidencebased guidelines [21] . In the GWTG-CAD, hospitals that received a performance award program attained 85% adherence with 6 performance measures for at least 12 consecutive months [22] . There was no specific follow-up program after the GAP intervention.
Our results also showed that patients undergoing CABG were less likely to receive key discharge medications when compared with PCI patients. It has been suggested that lack of specific randomized trials supporting their use in post-CABG patients may be responsible for these lower prescription rates [11] . However, their use in post-CABG patients is generally endorsed by the national guidelines and has great potential for improvement in care after an AMI [23, 24] . It is possible that the younger age of PCI patients or more consistent use of standardized protocols for their care may explain the PCI advantage [11, 25] .
In addition to the procedures, we found that older patients appeared less likely to be prescribed any guideline-recommended medications, with the exception of BBs, consistent with other studies showing underutilization of medications in elderly AMI patients [26] . This pattern may be attributed to fear of adverse effects in more comorbid elderly patients. However, it has also P < 0.001 P < 0.001 P < 0.001 P < 0.001
Ns vary due to varying numbers of patients with contraindications. *P < 0.05, **P < 0.01, ***significant contrast between hospital. CHF, congestive heart failure; MI, myocardial infarction.
been shown that such patients are likely to derive the greatest benefits from these types of medications [3] . We found that men were more likely than women to receive aspirin and BBs at discharge. Earlier studies have also shown that women receive somewhat less aggressive treatment during management of AMI [27, 28] , but the reasons remain unclear. Jani et al. [20] , however, documented that women in the GAP program were less likely to use GAP discharge tools, and this may account for the gender differences in the rate of medication use. As with gender differences, it remains unclear why white patients were less likely (than minority patients, most of whom were African Americans) to receive prescriptions for ACEI and aspirin/Plavix at discharge.
Our findings of substantial variation in prescription rates among individual hospitals, independent of in-hospital treatment and AMI patient characteristics, again point to the importance of implementing QI process improvement. In particular, none of the hospitals consistently displayed the highest or lowest discharge prescription rates for all the medications examined, meaning these patterns do not simply reveal 'problem institutions'. There is an overall need for hospitals to design strategies to improve processes that can lead to sustainable QI initiative gains after initial implementation. There are indications that a mechanism of rapid data collection and feedback to individual physicians and hospitals, along with summary comparative data, could serve as a means of decreasing the differences among hospitals [19, 29] . This process enables the group to reflect, in almost real time, about the measured performance, offering the opportunity to consider and improve quality-of-care levels [29] . Leadership support, interdisciplinary teams, concentrating on specific proven care components, standardized and transparent work processes and continuous audit and feedback have been suggested as some of the key concepts for sustainability for any improvement initiative [22, 30] .
Study limitations
Our study has some limitations. Our results are based on the comparison of a historical cohort of AMI patients in the same mid-Michigan hospitals 1 year apart. While such comparisons could be subject to biases arising from differences in cohort characteristics and historical changes in the institutions unrelated to the GAP project, we believe that the current comparison does shed light on the sustainability of such a QI initiative in typical settings. Furthermore, we only studied AMI patients who were ideal and had no contraindications for each medication used in each cohort, thus making any differences observed in the two cohorts negligible. Since the comparisons were also based on AMI patients admitted to the same hospitals in the same two communities, the threat of selection bias also appears small.
In summary, our study revealed that the early benefits of the Mid-Michigan GAP initiative on guideline use were only partially sustained at 1 year. Furthermore, our findings of lower rates of adherence to medication quality indicators in patients undergoing CABG, gender differences in the use of aspirin and BB at discharge and significant differences among hospitals in adherence rates suggest that there is substantial room for improvement, particularly through targeted future QI efforts. Improved focused attention to correcting the decline at discharge may produce the greatest improvement in longer-term patient outcomes.
